249 related articles for article (PubMed ID: 24604623)
1. Hepatocellular carcinoma and nodular regenerative hyperplasia after chemotherapy for metastatic colorectal carcinoma.
Calderaro J; Azoulay D; Zafrani ES
Hepatology; 2014 Oct; 60(4):1440-1. PubMed ID: 24604623
[No Abstract] [Full Text] [Related]
2. [Regenerative nodular hyperplasia of the liver related to oxaliplatin-based chemotherapy].
Béchade D; Désolneux G; Fonck M; Soubeyran I; Bécouarn Y; Evrard S
Presse Med; 2013 Jan; 42(1):102-7. PubMed ID: 22770975
[No Abstract] [Full Text] [Related]
3. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
[TBL] [Abstract][Full Text] [Related]
4. Splenic artery ligation for severe oxaliplatin induced portal hypertension: a way to improve postoperative course and allow adjuvant chemotherapy for colorectal liver metastases.: Letter to editor: comment about "Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases".
Schwarz L; Faitot F; Soubrane O; Scatton O
Eur J Surg Oncol; 2014 Jun; 40(6):787-8. PubMed ID: 24613742
[No Abstract] [Full Text] [Related]
5. Oxaliplatin in colorectal cancer: an overview.
Armand JP; Boige V; Raymond E; Fizazi K; Faivre S; Ducreux M
Semin Oncol; 2000 Oct; 27(5 Suppl 10):96-104. PubMed ID: 11049040
[No Abstract] [Full Text] [Related]
6. A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy.
Hewes JC; Riddy D; Morris RW; Woodrooffe AJ; Davidson BR; Fuller B
J Hepatol; 2006 Aug; 45(2):263-70. PubMed ID: 16635536
[TBL] [Abstract][Full Text] [Related]
7. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation.
Agostini J; Benoist S; Seman M; Julié C; Imbeaud S; Letourneur F; Cagnard N; Rougier P; Brouquet A; Zucman-Rossi J; Laurent-Puig P
J Hepatol; 2012 Apr; 56(4):869-76. PubMed ID: 22200551
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACHBT). Short version.
Zalinski S; Mariette C; Farges O; ; ;
J Visc Surg; 2011 Jun; 148(3):e171-82. PubMed ID: 21703959
[No Abstract] [Full Text] [Related]
9. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
Rodriguez NA; Ascaso FJ
J Clin Oncol; 2011 Jun; 29(18):e532-3. PubMed ID: 21483009
[No Abstract] [Full Text] [Related]
10. Improved first-line chemotherapy: a better chance for surgery?
Tejpar S; Van Cutsem E; Adam R
Lancet Oncol; 2010 Jan; 11(1):4-5. PubMed ID: 19942480
[No Abstract] [Full Text] [Related]
11. [Liver resection. I].
Oldhafer KJ; Stavrou GA
Zentralbl Chir; 2006 Oct; 131(5):W54-66; quiz W67-8. PubMed ID: 17089283
[No Abstract] [Full Text] [Related]
12. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A
Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914
[TBL] [Abstract][Full Text] [Related]
13. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
Pessaux P; Panaro F; Casnedi S; Zeca I; Marzano E; Bachellier P; Jaeck D; Chenard MP
Eur J Surg Oncol; 2010 Jun; 36(6):575-82. PubMed ID: 20452168
[TBL] [Abstract][Full Text] [Related]
14. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
15. Fibrolamellar hepatocellular carcinoma arising in a background of focal nodular hyperplasia: a report of 2 cases.
Imkie M; Myers SA; Li Y; Fan F; Bennett TL; Forster J; Tawfik O
J Reprod Med; 2005 Aug; 50(8):633-7. PubMed ID: 16220774
[TBL] [Abstract][Full Text] [Related]
16. Liver function considerations for post-selective internal radiation therapy resection (hepatocellular carcinoma and metastatic colorectal cancer).
Sangro B
Future Oncol; 2014 Nov; 10(15 Suppl):57-9. PubMed ID: 25478769
[No Abstract] [Full Text] [Related]
17. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin-induced immune mediated thrombocytopenia.
Beg MS; Komrokji RS; Ahmed K; Safa MM
Cancer Chemother Pharmacol; 2008 Oct; 62(5):925-7. PubMed ID: 18204841
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin-related hyperammonaemic encephalopathy in a patient with colon cancer.
Chang YY; Lin JK; Jiang JK
Colorectal Dis; 2012 Dec; 14(12):e821. PubMed ID: 22330089
[No Abstract] [Full Text] [Related]
20. Severe anaphylactic reaction to oxaliplatin.
Alliot C; Messouak D; Beets C; Rapin JP
Clin Oncol (R Coll Radiol); 2001; 13(3):236. PubMed ID: 11527302
[No Abstract] [Full Text] [Related]
[Next] [New Search]
